Lion Point Capital’s Royalty Pharma RPRX Stock Holding History

Lion Point Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Hold	21,400	–	–	5.74%	5
2026 Q1	$1.03M	Hold	21,400	–	–	6.14%	3
2025 Q4	$827K	Hold	21,400	–	–	4.28%	7
2025 Q3	$755K	Buy	+21,400	New	+$775K	4.29%	11

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lion Point Capital's RPRX Position: Q2 2026 in Review

Lion Point Capital held its Royalty Pharma (RPRX) position steady in Q2 2026 at 21,400 shares worth $1.2M. The position accounts for 5.74% of the portfolio, ranked #5.

Lion Point Capital first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Lion Point Capital held 21,400 shares of Royalty Pharma worth $1.2M as of Q2 2026.
Lion Point Capital left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 5.74% of Lion Point Capital's portfolio in Q2 2026, its #5 holding.
Lion Point Capital first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.